Abstract
AIM:
The aim of the study was to study the efficacy of modified electroconvulsive therapy (MECT) as an augmentation agent in schizophrenia, with particular emphasis in treatment-resistant schizophrenia.
MATERIAL AND METHODS:
A prospective open-label, raters blinded within a group interventional study done over 1 year with 40 consenting adults with a diagnosis of treatment-resistant schizophrenia as per Conley and Kelly’s criteria. With preanesthetic clearance, they were put on a supervised regular MECT regimen after baseline clinical global impression (CGI), PANSS, and Brief Psychiatric Rating Scale (BPRS) application with improvement recorded by repeat application of psychopathology measurement scales.
RESULTS:
after a mean of 11.10 ± 1.6 MECT sessions ranging from 8 to 14, we observed an improvement of 30.6% ± 3.5% in total PANSS score with significant improvement in CGI and BPRS.
CONCLUSION:
The study endorses the efficacy of MECT augmentation in treatment-resistant schizophrenia.
Recommended Citation
Singh, Chitrakshee; Kumar, Sudhir; Pandey, Abhinav; and Singh, Paramvir
(2024)
"Efficacy of modified electroconvulsive therapy as augmentation agent in treatment-resistant schizophrenia,"
Indian Journal of Health Sciences and Biomedical Research KLEU: Vol. 17:
Iss.
3, Article 13.
DOI: https://doi.org/10.4103/kleuhsj.kleuhsj_239_23
Available at:
https://kleijhsbr.researchcommons.org/journal/vol17/iss3/13
Pages
250
Last Page
254
Copyright
Copyright: © 2024 Indian Journal of Health Sciences and Biomedical Research KLEU
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.